Guardant Health, Inc., a leader in precision oncology, has announced the introduction of FPG 360, a new in-house liquid biopsy testing service at Fondazione Policlinico Universitario Agostino Gemelli IRCCS in Rome, Italy. This initiative represents the latest collaboration between Guardant Health and top European academic and research hospitals, combining innovative technology with existing care practices to increase access to advanced cancer diagnostics.
Health Technology Insights: Hallmark Health Forms Executive Advisory Board
The service at Policlinico Gemelli will utilize Guardant360® CDx technology to provide on-site liquid biopsy testing. This collaboration enhances the availability of precision oncology diagnostics and supports both standard patient care and ongoing clinical research. FPG 360 is among the first dedicated liquid biopsy laboratories in Italy to operate within a hospital setting. Policlinico Gemelli, one of the largest and most respected hospitals in Italy, treats thousands of cancer patients each year through its comprehensive cancer center, which offers advanced diagnostic, treatment, and research capabilities.
This launch builds on Guardant Health’s previous partnerships with Val d’Hebron/VHIO in Barcelona and The Royal Marsden Hospital in London.
Health Technology Insights: TestDynamics Launches Unified Medical Imaging AI System
Helmy Eltoukhy, Chairman and co-CEO of Guardant Health, said the partnership demonstrates how public healthcare institutions and private innovation can work together to provide broader access to blood-based cancer profiling and genomic insights. He emphasized that introducing this technology at a leading European cancer center is an important step toward enabling clinicians to develop more personalized treatment plans and improve patient outcomes.
Professor Antonio Gasbarrini, Scientific Director of Policlinico Gemelli IRCCS, stated that the new service is a significant advancement for Italian cancer patients, allowing them to access comprehensive genomic profiling liquid biopsy testing locally without needing to send samples abroad.
In Italy, approximately 400,000 new cancer cases are diagnosed each year. Tumors account for around three deaths per 1,000 people annually, including about 3.5 per 1,000 men and 2.5 per 1,000 women. Guardant Health’s tests are used by oncologists worldwide to guide treatment for solid tumor cancers and by pharmaceutical companies and academic researchers in clinical trials to advance precision medicine.
Last year, Guardant Health received certification for its Guardant360® CDx blood test under the European Union’s In Vitro Diagnostic Regulation 2017/746. TÜV SÜD Product Service certified the test for profiling tumor mutations in patients with any solid tumor and as a companion diagnostic to identify patients who may benefit from targeted therapies for advanced non-small cell lung cancer and breast cancer.
Health Technology Insights: IKS Health Appoints New Chief Marketing and Chief Legal and Compliance Officers
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
